This is a text-only preview. Log in or sign up to view the full document.

    PART I—FINANCIAL INFORMATION

    ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

    SYNAPTICS INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in millions, except par value and share amounts)

    (unaudited)

    March 2026

    June 2025

    Current assets:

    Cash and cash equivalents

    Short-term investments

    Accounts receivable, net

    Inventories

    Prepaid expenses and other current assets

    Property and equipment, net

    Goodwill

    Acquired intangible assets

    Deferred tax assets

    Non-current other assets

    LIABILITIES AND STOCKHOLDERS’ EQUITY

    Current liabilities:

    Accounts payable

    Accrued liabilities

    Long-term debt

    Other long-term liabilities

    Stockholders' equity:

    Preferred stock:

    $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding

    Common stock:

    $0.001 par value; 120,000,000 shares authorized, 71,878,081 and 70,611,845 shares issued,

    38,735,446 and 38,642,761 shares outstanding, at March 2026 and June 2025, respectively

    Additional paid-in capital

    Treasury stock: 33,142,635 and 31,969,084 common shares at March 2026 and June 2025, respectively, at cost

    Retained earnings

    Total stockholders' equity

    Total liabilities and stockholders' equity

    See accompanying notes to condensed consolidated financial statements (unaudited)

    SYNAPTICS INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in millions, except per share data)

    (unaudited)

    Three Months Ended

    Nine Months Ended

    March

    Net revenue

    Cost of revenue

    Gross margin

    Operating expenses:

    Research and development

    Selling, general, and administrative

    Sign up or log in to view this filing

    Create a free CapEdge account to read the full document, search inside it, and export tables.